CAMBRIDGE, Mass., March 19, 2025 (GLOBE NEWSWIRE) -- Akebia Therapeutics ®, Inc. (“Akebia”) (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted ...

Akebia Therapeutics' stock is down 28% after a proposed stock offering, with declining Auryxia revenues and significant financial challenges. Vafseo's market launch shows some promise, but it's a ...

Piper Sandler raised the firm’s price target on Akebia (AKBA) to $6 from $4 and keeps an Overweight rating on the shares. The firm says it remains a buyer of Akebia shares following Q4 reporting ...

Akebia plans to kick off a phase 3 trial to assess Vafseo as a potential treatment for anemia in late-stage CKD patients who aren’t on dialysis.

Akebia Therapeutics shares were down 20% to $2.27 after the company priced its underwritten public offering of 25 million shares at $2 a share. All shares are being offered by Akebia. The proceeds ...

Akebia Therapeutics, Inc. has announced the commencement of an underwritten public offering of its common stock, with all shares being offered by the company itself. Akebia plans to give ...

Akebia Therapeutics AKBA recently announced that it is floating a secondary issue of 25 million shares of its common stock to the public at an issue price of $2 per share, amounting to $50 million.

CAMBRIDGE, Mass. - Akebia Therapeutics, Inc. (NASDAQ: AKBA), a biopharmaceutical company focusing on kidney disease treatments with a current market capitalization of $673 million, announced today ...

Akebia Therapeutics (AKBA) came out with a quarterly loss of $0.10 per share versus the Zacks Consensus Estimate of a loss of $0.08. This compares to break-even earnings per share a year ago.